Hovione

Ivan Villax - 1950

Hovione continues to be a privately held company with 5 plants - in Portugal (1969), Macao (1986), New Jersey (2001) expanded in 2016,[1] Taizhou in mainland China (2008) and Cork, Ireland (2009) - have a total reactor capacity of 1300 m³ and 1100 people worldwide. Since Hovione started operations in 1959, the company has patented more than 100 innovative chemical processes and produced industrially over 45 different APIs. All Hovione sites have been successfully inspected either by FDA, European Medicines Agency or the PMDA Japanese agency.[2][3][4][5]

Hovione is a major source of semi-synthetic tetracyclines and corticosteroids, and is the largest independent supplier of contrast agents – these three families of compounds make up most of its generic product portfolio. The other half of the business focuses on exclusive projects:[6][7]

• Development and manufacture of innovator APIs
• Particle Engineering: manipulations of physical properties of APIs, polymeric encapsulation
• Development of formulations for pulmonary delivery

Hovione has two R&D centers with a team of over 270 scientists, one in Portugal - Loures and another one in its facilities in New Jersey. Hovione has international partnerships, including with Cambridge and MIT.[8] In 2016, 7 PhDs were simultaneously running and it has launched a scientific program named "9oW",[9] which challenges scientific and academic communities to help overcoming technological challenges. Also, Hovione is already the largest private employer of doctorates in Portugal (57 doctorates in Loures).[10]

Hovione was always present in the pharmaceutical industry offering products and services related to the development and manufacture of either a new chemical entity (NCE) for an exclusive contract manufacturing partner or an existing API for an off-patent product. In nowadays it is an integrated solution provider, from process chemistry to particle engineering to formulation,[11] from very small scale to full commercial capacity and from preclinical to market. In the area of technologies, it has capabilities in spray drying (also for potent drugs), spray congealing, fluidized spray drying, aseptic spray drying, jet milling, controlled crystallization, microfluidization, continuous manufacturing,[12] continuous tableting.[13] And methodologies Quality by Design,[14] process analytical technology (PAT), britest, lean, scale-up science, modeling. Hovione invested about $100 million in 2017 and plans to spend as much again this year and next. The plan over the next three years is to continue investing, especially in Portugal, where the firm will add 165 m³ of chemical synthesis capacity, a spray-dryer building, and a 1,200-m² analytical lab.[15]

• Hovione Website